In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Berchtold Holding AG

Division of Stryker Corp.
www.berchtold.biz/en

Latest From Berchtold Holding AG

Medtechs At The Wheel In New Health Care Landscape

2016 was a year of surprise and change in political circles, but that's nothing new for the medtech industry, which over a number of years has become accustomed to health care systems demanding different and ever-higher levels of service. Smart medtechs have been ahead of the curve, but the whole industry now factors in clients' wider needs in a holistic approach to patient care. Many companies' current M&A policies are already reflecting the changes to come.

M & A Deals

Deals Shaping The Medical Industry, July/August 2014

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced May and June 2014.

BioPharmaceutical Medical Device

Device/Diagnostics Quarterly Deal Statistics, Q1 2014

Device financing dropped more than 40% to $714 million in Q1; Smith & Nephew’s $1.7 billion acquisition of ArthroCare overshadowed acquisitions. Diagnostics companies raised $568 million, a 34% increase over 2013’s final quarter; nonprofits provided assets to diagnostics firms in multiple licensing arrangements.

Medical Device Deals

Deals In Depth: February 2014

Actavis significantly improved its US presence though its $24 billion purchase of Forest Labs, while Myriad exercised its option to buy fellow molecular diagnostics company Crescendo. Public offerings – IPOs and follow-ons – dominated both biopharma and device financing.

BioPharmaceutical Medical Device
See All

Company Information

  • Industry
  • Medical Devices
    • Surgical Equipment & Devices
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Berchtold GMBH
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Germany
  • Parent & Subsidiaries
  • Stryker Corp.
  • Senior Management
  • Theo Fritz, CEO
  • Contact Info
  • Berchtold Holding AG
    Phone: (49) 7461 181-0
    Ludwigstaler Straße 25
    Tuttlingen, 78532
    Germany
Advertisement
Advertisement
UsernamePublicRestriction

Register